Literature DB >> 6684209

Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion.

J R Sullivan, M J Leyden, R Bell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6684209     DOI： 10.1056/NEJM198309293091317

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.

Authors:  B Chevallier; P Cappelaere; T Splinter; M Fabbro; J L Wendling; L Cals; G Catimel; M Giovannini; D Khayat; P Bastit; N Claverie
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

2.  Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.

Authors:  D Tsuji; M Yokoi; K Suzuki; T Daimon; M Nakao; H Ayuhara; Y Kogure; K Shibata; T Hayashi; K Hirai; K Inoue; T Hama; K Takeda; M Nishio; K Itoh
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

3.  Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.

Authors:  Mari Yokoi; Daiki Tsuji; Kenichi Suzuki; Yohei Kawasaki; Masahiko Nakao; Hideaki Ayuhara; Yuuki Kogure; Kazuhiko Shibata; Toshinobu Hayashi; Keita Hirai; Kazuyuki Inoue; Toshihiro Hama; Koji Takeda; Makoto Nishio; Kunihiko Itoh
Journal:  Support Care Cancer       Date:  2017-11-24       Impact factor: 3.603

Review 4.  Methodological issues in antiemetic studies.

Authors:  M Aapro
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

5.  Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

Authors:  Sun Young Rha; Yeonhee Park; Su Kyung Song; Chung Eun Lee; Jiyeon Lee
Journal:  Support Care Cancer       Date:  2016-03-16       Impact factor: 3.603

Review 6.  5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.

Authors:  R E Gregory; D S Ettinger
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

7.  Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.

Authors:  Hiroyoshi Takemoto; Junichi Nishimura; Takamichi Komori; Ho Min Kim; Hirofumi Ota; Rei Suzuki; Masakazu Ikenaga; Masataka Ikeda; Hirofumi Yamamoto; Taroh Satoh; Taishi Hata; Ichiro Takemasa; Tsunekazu Mizushima; Yuichirou Doki; Masaki Mori
Journal:  Int J Clin Oncol       Date:  2016-07-27       Impact factor: 3.402

8.  Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.

Authors:  J Latreille; D Stewart; F Laberge; P Hoskins; J Rusthoven; E McMurtrie; D Warr; L Yelle; D Walde; F Shepherd
Journal:  Support Care Cancer       Date:  1995-09       Impact factor: 3.603

9.  Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline-based regimens.

Authors:  Hideyuki Ohzawa; Atsushi Miki; Yasuo Hozumi; Chieko Miyazaki; Yuka Sagara; Yumiko Tanaka; Satomi Shiba; Hiromi Joutoku; Masako Sakuragi; Megumi Takehara; Yasunaru Sakuma; Wataru Nishimura; Hirofumi Fujii; Yoshikazu Yasuda
Journal:  Oncol Lett       Date:  2014-10-24       Impact factor: 2.967

10.  Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.

Authors:  Hideki Takeuchi; Toshiaki Saeki; Keisuke Aiba; Kazuo Tamura; Kenjiro Aogi; Kenji Eguchi; Kenji Okita; Yoshikazu Kagami; Ryuhei Tanaka; Kazuhiko Nakagawa; Hirofumi Fujii; Narikazu Boku; Makoto Wada; Tatsuo Akechi; Yasuhiro Udagawa; Yutaka Okawa; Yusuke Onozawa; Hidenori Sasaki; Yasuo Shima; Naohito Shimoyama; Masayuki Takeda; Toshihiko Nishidate; Akifumi Yamamoto; Tadashi Ikeda; Koichi Hirata
Journal:  Int J Clin Oncol       Date:  2015-06-17       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.